The Food and Drug Administration recently limited certain monoclonal antibody drugs used to treat COVID patients, because they don't seem to be effective against the omicron variant.
“People are tired, and we’ve seen a significant resurgence here. There’s a significant demand in our emergency rooms, in our COVID unit, in our ICU, and so, we need all hands on deck.”